{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:02:08Z","timestamp":1789524128545,"version":"build-2803163510"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":78,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"DOI":"10.1186\/s12889-026-28336-7","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:57:43Z","timestamp":1782781063000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost effectiveness and public health impact of PCV20 among adults in France"],"prefix":"10.1186","volume":"26","author":[{"given":"St\u00e9phane","family":"Fi\u00e9vez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Menara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucile","family":"Bellier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Sivignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Vietri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"issue":"1","key":"28336_CR1","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1186\/s12879-021-06669-5","volume":"21","author":"E Blanc","year":"2021","unstructured":"Blanc E, Chaize G, Fievez S, F\u00e9ger C, Herquelot E, Vainchtock A, et al. The impact of comorbidities and their stacking on short- and long-term prognosis of patients over 50 with community-acquired pneumonia. BMC Infect Dis. 2021;21(1):949. https:\/\/doi.org\/10.1186\/s12879-021-06669-5.","journal-title":"BMC Infect Dis"},{"issue":"12","key":"28336_CR2","doi-asserted-by":"publisher","first-page":"ofz510","DOI":"10.1093\/ofid\/ofz510","volume":"6","author":"K Danis","year":"2019","unstructured":"Danis K, Varon E, Lepoutre A, Janssen C, Forestier E, Epaulard O, et al. Factors associated with severe nonmeningitis invasive pneumococcal disease in adults in France. Open Forum Infect Dis. 2019;6(12):ofz510. https:\/\/doi.org\/10.1093\/ofid\/ofz510. PubMed PMID: 31868865.","journal-title":"Open Forum Infect Dis"},{"issue":"19","key":"28336_CR3","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1016\/j.vaccine","volume":"34","author":"V Personne","year":"2016","unstructured":"Personne V, Chevalier J, Buffel du Vaure C, Partouche H, Gilberg S, de Pouvourville G. CAPECO: Cost evaluation of community acquired pneumonia managed in primary care. Vaccine. 2016;34(19):2275\u201380. https:\/\/doi.org\/10.1016\/j.vaccine. 2016.03.013 PubMed PMID: 26979138.","journal-title":"Vaccine"},{"key":"28336_CR4","doi-asserted-by":"publisher","unstructured":"Tubiana S, Varon E, Biron C, Ploy MC, Mourvillier B, Taha MK et al. Community-acquired bacterial meningitis in adults: in-hospital prognosis, long-term disability and determinants of outcome in a multicentre prospective cohort. 26. 2020;26(9):1192\u2013200. https:\/\/doi.org\/10.1016\/j.cmi.2019.12.020. PubMed PMID: 31927117.","DOI":"10.1016\/j.cmi.2019.12.020"},{"issue":"7","key":"28336_CR5","doi-asserted-by":"publisher","first-page":"ofae349","DOI":"10.1093\/ofid\/ofae349","volume":"11","author":"A Sabra","year":"2024","unstructured":"Sabra A, Bourgeois M, Blanc E, Fievez S, Mo\u00efsi J, Goussiaume G, et al. Hospital Burden of All-Cause Pneumonia and Nonbacteremic Pneumococcal Pneumonia in Adults in France Between 2013 and 2019. Open Forum Infect Dis. 2024;11(7):ofae349. https:\/\/doi.org\/10.1093\/ofid\/ofae349.","journal-title":"Open Forum Infect Dis"},{"key":"28336_CR6","unstructured":"Haut Conseil de la Sant\u00e9 Publique. Infections \u00e0 pneumocoque: recommandations vaccinales pour les adultes. Paris: Rapport de l\u2019HCSP; 2017."},{"issue":"33","key":"28336_CR7","doi-asserted-by":"publisher","first-page":"4911","DOI":"10.1016\/j.vaccine.2022.06.071","volume":"40","author":"B Wyplosz","year":"2022","unstructured":"Wyplosz B, Fernandes J, Sultan A, Roche N, Roubille F, Loubet P, et al. Pneumococcal and influenza vaccination coverage among at-risk adults: A 5-year French national observational study. Vaccine. 2022;40(33):4911\u201321. https:\/\/doi.org\/10.1016\/j.vaccine.2022.06.071.","journal-title":"Vaccine"},{"key":"28336_CR8","unstructured":"Wyplosz B, Loubet P, Cases A, Grenier B, Raguideau F, Blanc E, Low pneumococcal vaccination coverage in France: would a vaccination in the 65\u2009+\u2009help identifying at-risk population? In., Barcelona et al. Spain; 2024."},{"key":"28336_CR9","unstructured":"Goussiaume G, Wyplosz B, Blanc E, Sultan A, Fernandes J, Foug\u00e8re B et al. Estimation des couvertures vaccinales pneumococciques et antigrippales des adultes \u00e0 risque en France en 2020. 2024. Available from: https:\/\/mediatheque.synprefh.cyim.com\/mediatheque\/media.aspx?mediaId=195514&channel=23854."},{"issue":"8","key":"28336_CR10","doi-asserted-by":"publisher","first-page":"e0329703","DOI":"10.1371\/journal.pone.0329703","volume":"20","author":"B Wyplosz","year":"2025","unstructured":"Wyplosz B, Grenier B, Roche N, Roubille F, Loubet P, Sultan A, Foug\u00e8re B, Fernandes J, Duhot D, Moulin B, Raguideau F, Blanc E, Goussiaume G. Pneumococcal vaccination at 65 years and vaccination coverage in at-risk adults: A retrospective population-based study in France. PLoS ONE. 2025;20(8):e0329703.","journal-title":"PLoS ONE"},{"key":"28336_CR11","unstructured":"PneuVUE\u00ae. A new view into Pneumonia among adults 65 years and over. Available at: https:\/\/www.ipsos.com\/en-uk\/pneuvue-new-view-pneumonia-among-adults-65-years-and-over"},{"key":"28336_CR12","unstructured":"Vaccination. des populations \u00e0 risques qui s\u2019ignorent et un pl\u00e9biscite pour une simplification du parcours vaccinal. Available at https:\/\/www.ipsos.com\/fr-fr\/vaccination-des-populations-risques-qui-signorent-et-un-plebiscite-pour-une-simplification-du-parcours-vaccinal"},{"key":"28336_CR13","unstructured":"Avis relatif aux recommandations de la vaccination pour les adultes. et les enfants \u00e2g\u00e9s de plus de 2 ans \u00e0 risque d\u2019infection invasive \u00e0 pneumocoque. Haut Conseil de la sant\u00e9 publique. 2013. Available from: https:\/\/www.hcsp.fr\/Explore.cgi\/AvisRapportsDomaine?clefr=355."},{"key":"28336_CR14","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Strat\u00e9gie de vaccination contre les infections \u00e0 pneumocoque - Place du vaccin pneumococcique polyosidique conjugu\u00e9 (20-valent, adsorb\u00e9) chez l\u2019adulte. 2023. Available from: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2023-08\/strategie_de_vaccination_contre_les_infections_a_pneumocoque_place_du_vaccin_pneumococcique_polyosidique_conjugue_20-valent_.pdf."},{"key":"28336_CR15","unstructured":"Haute Autorit\u00e9 de sant\u00e9. \u00c9largissement des crit\u00e8res d\u2019\u00e9ligibilit\u00e9 \u00e0 la vaccination antipneumococcique chez les adultes - Place du vaccin PREVENAR-20 chez les adultes s\u00e9niors, tous niveaux de risque inclus. 2024. Available from: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2025-01\/eco_sp_446_vaccination_pneumocoques_adultes_vf_1.pdf."},{"issue":"9","key":"28336_CR16","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1080\/21645515.2015.1011957","volume":"11","author":"X Bresse","year":"2015","unstructured":"Sant\u00e9 Publique France. Infections invasives bact\u00e9riennes en 2022. Bilan des donn\u00e9es de surveillance du r\u00e9seau Epibac. 2024.","journal-title":"Hum Vaccines Immunother"},{"key":"28336_CR17","doi-asserted-by":"crossref","unstructured":"Jiang Y, Gervais F, Gauthier A, Baptiste C, Martinon P, Bresse X. A comparative public health and budget impact analysis of pneumococcal vaccines: The French case. Hum Vaccines Immunother. 2015;11(9):2188\u201397.","DOI":"10.1080\/21645515.2015.1011957"},{"issue":"1","key":"28336_CR18","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1080\/14760584.2023.2262575","volume":"22","author":"F K\u00fchne","year":"2023","unstructured":"K\u00fchne F, Achtert K, P\u00fcschner F, Urbanski-Rini D, Schiller J, Mahar E, et al. Cost-effectiveness of use of 20-valent pneumococcal conjugate vaccine among adults in Germany. Expert Rev Vaccines. 2023;22(1):921\u201332. https:\/\/doi.org\/10.1080\/14760584.2023.2262575. PubMed PMID: 37881844.","journal-title":"Expert Rev Vaccines"},{"issue":"5","key":"28336_CR19","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1183\/13993003.00325-2015","volume":"46","author":"MJJ Mangen","year":"2015","unstructured":"Mangen MJJ, Rozenbaum MH, Huijts SM, van Werkhoven CH, Postma DF, Atwood M, et al. Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands. Eur Respir J. 2015;46(5):1407\u201316. https:\/\/doi.org\/10.1183\/13993003.00325-2015 . PubMed PMID: 26160871; PubMed Central PMCID: PMC4750466.","journal-title":"Eur Respir J"},{"issue":"1","key":"28336_CR20","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1080\/14760584.2023.2273892","volume":"22","author":"S Marbaix","year":"2023","unstructured":"Marbaix S, Mignon A, Taelman A, Averin A, Atwood M, Vietri J. Cost-utility of 20-valent pneumococcal conjugate vaccine compared to no vaccination and recommended alternative vaccines among Belgian adults. Expert Rev Vaccines. 2023;22(1):1008\u201321. https:\/\/doi.org\/10.1080\/14760584.2023.2273892. PubMed PMID: 37872765.","journal-title":"Expert Rev Vaccines"},{"issue":"8","key":"28336_CR21","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1080\/14737167.2022.2134120","volume":"22","author":"D Mendes","year":"2022","unstructured":"Mendes D, Averin A, Atwood M, Sato R, Vyse A, Campling J, et al. Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease. Expert Rev Pharmacoecon Outcomes Res. 2022;22(8):1285\u201395. .2134120 PubMed PMID: 36225103.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"28336_CR22","unstructured":"Haute Autorit\u00e9 de Sant\u00e9: Choix m\u00e9thodologiques pour l\u2019\u00e9valuation \u00e9conomique. 2020. Available from: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2020-07\/guide_methodologique_evaluation_economique_has_2020_vf.pdf."},{"key":"28336_CR23","doi-asserted-by":"publisher","unstructured":"Partouche H, Lepoutre A, Vaure CB du, Poisson T, Toubiana L, Gilberg S. Incidence of all-cause adult community-acquired pneumonia in primary care settings in France. M\u00e9decine Mal Infect. 2018;48(6):389\u201395. https:\/\/doi.org\/10.1016\/j.medmal.2018.02.012.","DOI":"10.1016\/j.medmal.2018.02.012"},{"key":"28336_CR24","doi-asserted-by":"publisher","first-page":"15010","DOI":"10.1038\/npjpcrm.2015.10","volume":"25","author":"H Partouche","year":"2015","unstructured":"Partouche H, Buffel du Vaure C, Personne V, Le Cossec C, Garcin C, Lorenzo A, et al. Suspected community-acquired pneumonia in an ambulatory setting (CAPA): a French prospective observational cohort study in general practice. NPJ Prim Care Respir Med. 2015;25:15010. https:\/\/doi.org\/10.1038\/npjpcrm.2015.10. PubMed PMID: 25763466; PubMed Central PMCID: PMC4373492.","journal-title":"NPJ Prim Care Respir Med"},{"key":"28336_CR25","doi-asserted-by":"publisher","unstructured":"Luong LB, Duval X, Botelho-Nevers E, Lain\u00e9 F, Hernu R, Blanc E, Esposito Farese M, Launay O, Burdet C. R\u00e9partition des s\u00e9rotypes de vaccins pneumococciques contenus dans le vaccin dans les pneumonies communautaires n\u00e9cessitant une hospitalisation chez l\u2019adulte en France. 2024;8634(1002):S1-S174. https:\/\/doi.org\/10.1016\/j.mmifmc.2024.04.362.\u00a0ISSN 2772\u20137432.","DOI":"10.1016\/j.mmifmc.2024.04.362"},{"key":"28336_CR26","unstructured":"INSEE. Population par \u00e2ge en 2024 - France - TABLEAU DE BORD DE L\u2019\u00c9CONOMIE FRAN\u00c7AISE. Available from: https:\/\/www.insee.fr\/fr\/statistiques\/4277619?sommaire=4318291."},{"key":"28336_CR27","doi-asserted-by":"publisher","unstructured":"Ara R, Brazier JE. Using Health State Utility Values from the General Population to Approximate Baselines in Decision Analytic Models when Condition-Specific Data are Not Available. Value Health. 2011;14(4):539\u201345. https:\/\/doi.org\/10.1016\/j.jval.2010.10.029.","DOI":"10.1016\/j.jval.2010.10.029"},{"issue":"9","key":"28336_CR28","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1007\/s10198-022-01559-2","volume":"24","author":"L Gautier","year":"2023","unstructured":"Gautier L, Azzi J, Saba G, Bonnelye G, de Pouvourville G. Population norms in France with EQ-5D-5L: health states, value indexes, and VAS. Eur J Health Econ. 2023;24(9):1517\u201330. https:\/\/doi.org\/10.1007\/s10198-022-01559-2.","journal-title":"Eur J Health Econ"},{"issue":"1","key":"28336_CR29","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12955-018-0854-6","volume":"16","author":"LF Andrade","year":"2018","unstructured":"Andrade LF, Saba G, Ricard JD, Messika J, Gaillat J, Bonnin P, Chidiac C, Illes HG, Laurichesse H, Detournay B, Petitpretz P, de Pouvourville G. Health related quality of life in patients with community-acquired pneumococcal pneumonia in France. Health Qual Life Outcomes. 2018;16(1):28.","journal-title":"Health Qual Life Outcomes"},{"issue":"5","key":"28336_CR30","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1016\/j.jval.2011.05.007","volume":"14","author":"J Galante","year":"2011","unstructured":"Galante J, Augustovski F, Colantonio L, Bardach A, Caporale J, Marti SG, et al. Estimation and Comparison of EQ-5D Health States\u2019 Utility Weights for Pneumoccocal and Human Papillomavirus Diseases in Argentina, Chile, and the United Kingdom. Value Health. 2011;14(5):S60\u20134. https:\/\/doi.org\/10.1016\/j.jval.2011.05.007. PubMed PMID: 21839901.","journal-title":"Value Health"},{"issue":"1","key":"28336_CR31","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/13696998.2025.2458957","volume":"28","author":"M Bailey","year":"2025","unstructured":"Bailey M, Farge G, Breau Brunel M, Mohanti S, Roy R, de Gem G, et al. Assessing the economic impact and healthcare resource utilization of inpatient pneumococcal disease among adults: a French national claims database study. J Med Econ. 2025;28(1):251\u20139. .2458957 PubMed PMID: 39866145.","journal-title":"J Med Econ"},{"key":"28336_CR32","unstructured":"Assurance Maladie. Base des m\u00e9dicaments et informations tarifaires. 2025;838. Available from: http:\/\/www.codage.ext.cnamts.fr\/codif\/bdm_it\/index.php?p_site=AMELI."},{"issue":"12","key":"28336_CR33","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","volume":"372","author":"MJM Bonten","year":"2015","unstructured":"Bonten MJM, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al. Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults. N Engl J Med. 2015;372(12):1114\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1408544.","journal-title":"N Engl J Med"},{"issue":"9","key":"28336_CR34","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1056\/NEJMoa0903029","volume":"362","author":"N French","year":"2010","unstructured":"French N, Gordon SB, Mwalukomo T, White SA, Mwafulirwa G, Longwe H, et al. A trial of 7-valent Pneumococcal Conjugate Vaccine in HIV-infected Adults. N Engl J Med. 2010;362(9):812. doi:10.1056\/NEJMoa0903029 PubMed PMID: 20200385.","journal-title":"N Engl J Med"},{"issue":"14","key":"28336_CR35","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1056\/NEJMoa035060","volume":"349","author":"KP Klugman","year":"2003","unstructured":"Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003;349(14):1341\u20138. doi:10.1056\/NEJMoa035060 PubMed PMID: 14523142.","journal-title":"N Engl J Med"},{"key":"28336_CR36","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.trivac.2016.04.004","volume":"5","author":"S Patterson","year":"2016","unstructured":"Patterson S, Webber C, Patton M. A post hoc assessment of duration of protection in CAPiTA (Community Acquired Pneumonia immunization Trial in Adults). Trials Vaccinol. 2016;5:92\u20136.","journal-title":"Trials Vaccinol"},{"key":"28336_CR37","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.eclinm.2018.12","volume":"6","author":"A Djennad","year":"2019","unstructured":"Djennad A, Ramsay ME, Pebody R, Fry NK, Sheppard C, Ladhani SN, et al. Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine and Changes in Invasive Pneumococcal Disease Incidence from 2000 to 2017 in Those Aged 65 and Over in England and Wales. EClinicalMedicine. 2019;6:42. https:\/\/doi.org\/10.1016\/j.eclinm.2018.12. 007 PubMed PMID: 31193709.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"28336_CR38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jinf.2012.02.017","volume":"65","author":"AJ van Hoek","year":"2012","unstructured":"van Hoek AJ, Andrews N, Waight PA, Stowe J, Gates P, George R, et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect. 2012;65(1):17\u201324. https:\/\/doi.org\/10.1016\/j.jinf.2012.02.017.","journal-title":"J Infect"},{"issue":"48","key":"28336_CR39","doi-asserted-by":"publisher","first-page":"6802","DOI":"10.1016\/j.vaccine.2012.09.019","volume":"30","author":"NJ Andrews","year":"2012","unstructured":"Andrews NJ, Waight PA, George RC, Slack MPE, Miller E. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine. 2012;30(48):6802\u20138. https:\/\/doi.org\/10.1016\/j.vaccine.2012.09.019.","journal-title":"Vaccine"},{"issue":"3","key":"28336_CR40","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1093\/cid\/ciab990","volume":"75","author":"B Essink","year":"2022","unstructured":"Essink B, Sabharwal C, Cannon K, Frenck R, Lal H, Xu X, et al. Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged\u2009\u2265\u200918 Years. Clin Infect Dis Off Publ Infect Dis Soc Am. 2022;75(3):390\u20138. PubMed PMID: 34940806; PubMed Central PMCID: PMC9427137.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"28336_CR41","unstructured":"Arr\u00eat\u00e9 du 31. mars 2022 portant approbation de la Convention nationale organisant les rapports entres les pharmaciens titulaires d\u2019officine et l\u2019assurance maladie - L\u00e9gifrance. Available from: https:\/\/www.legifrance.gouv.fr\/jorf\/id\/JORFTEXT000045538155."},{"key":"28336_CR42","unstructured":"La nomenclature g\u00e9n\u00e9rale des actes professionnels - NGAP. Available from: https:\/\/www.ameli.fr\/medecin\/exercice-liberal\/facturation-remuneration\/consultations-actes\/nomenclatures-codage\/ngap."},{"key":"28336_CR43","unstructured":"Tarifs conventionnels des m\u00e9decins g\u00e9n\u00e9ralistes. et sp\u00e9cialistes. Available from: https:\/\/www.ameli.fr\/medecin\/exercice-liberal\/facturation-remuneration\/consultations-actes\/tarifs\/tarifs-conventionnels-medecins-generalistes-specialistes. Cited 2026 Jun 1."},{"issue":"11","key":"28336_CR44","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.3390\/microorganisms11112781","volume":"11","author":"R Men\u00e9ndez","year":"2023","unstructured":"Men\u00e9ndez R, Torres A, Espa\u00f1a PP, Fern\u00e1ndez-Villar JA, Marim\u00f3n JM, M\u00e9ndez R, et al. Pneumococcal Serotypes Associated with Community-Acquired Pneumonia Hospitalizations in Adults in Spain, 2016\u20132020: The CAPA Study. Microorganisms. 2023;11(11):2781. https:\/\/doi.org\/10.3390\/microorganisms11112781.","journal-title":"Microorganisms"},{"issue":"7","key":"28336_CR45","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1016\/j.vaccine.2019.12.029","volume":"38","author":"C Stoecker","year":"2020","unstructured":"Stoecker C, Kobayashi M, Matanock A, Cho BH, Pilishvili T. Cost-effectiveness of continuing pneumococcal conjugate vaccination at age 65 in the context of indirect effects from the childhood immunization program. Vaccine. 2020;38(7):1770\u20137.","journal-title":"Vaccine"},{"key":"28336_CR46","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. avis d\u2019efficience Efluelda. 2020. Available at https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2020-10\/efluelda_25062020_avis_efficience_v3.pdf."},{"key":"28336_CR47","unstructured":"Haute Autorit\u00e9 de Sant\u00e9: avis \u00e9conomique Efluelda. 2025. Available at https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2025-05\/efluelda_15042025_avis_economique_ceesp_795.pdf."},{"key":"28336_CR48","unstructured":"Haute Autorit\u00e9 de Sant\u00e9: avis \u00e9conomique Shingrix. 2024. Available at https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2024-09\/shingrix_28052024_avis_economique.pdf."},{"key":"28336_CR49","unstructured":"Haute Autorit\u00e9 de Sant\u00e9: avis \u00e9conomique Nuvaxovid. 2024. Available at https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2024-09\/nuvaxovid_16042024_avis_economique.pdf."},{"key":"28336_CR50","unstructured":"Haute Autorit\u00e9 de Sant\u00e9: avis \u00e9conomique Vaxneuvance. 2024. Available at https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2024-02\/vaxneuvance_23012024_avis_economique.pdf."},{"key":"28336_CR51","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. avis d\u2019efficience Gardasil. 2017. Available at https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2017-12\/gardasil9_12092017_avis_efficience.pdf."},{"key":"28336_CR52","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. avis d\u2019efficience Fluenz Tetra. 2015. Available at https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2017-03\/fluenz_tetra_20150609_avis_efficience.pdf."},{"key":"28336_CR53","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. avis d\u2019efficience Rotateq. 2014. Available at https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2015-05\/rotateq_-_avis_masque.pdf."},{"key":"28336_CR54","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. avis d\u2019efficience Rotarix. 2014. Available at https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2015-05\/rotarix_-_avis_masque.pdf."},{"key":"28336_CR55","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. avis d\u2019efficience Zostavax. 2014. Available at https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2015-11\/zostavax_avis_defficience_m.pdf."},{"issue":"1","key":"28336_CR56","doi-asserted-by":"publisher","first-page":"104632","DOI":"10.1016\/j.idnow.2022.11.001","volume":"53","author":"C Plainvert","year":"2023","unstructured":"Plainvert C, Varon E, Viriot D, Kempf M, Plainvert C, Alauzet C, et al. Invasive pneumococcal infections in France: Changes from 2009 to 2021 in antibiotic resistance and serotype distribution of Streptococcus pneumoniae based on data from the French Regional Pneumococcal Observatories network. Infect Dis Now. 2023;53(1):104632.","journal-title":"Infect Dis Now"},{"issue":"1","key":"28336_CR57","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1080\/21645515.2020.1756669","volume":"17","author":"A Kopp","year":"2021","unstructured":"Kopp A, Mangin O, Gantzer L, Lekens B, Simoneau G, Ravelomanantsoa M, et al. Pneumococcal vaccination coverage in France by general practitioners in adults with a high risk of pneumococcal disease. Hum Vaccines Immunother. 2021;17(1):162\u20139. https:\/\/doi.org\/10.1080\/21645515.2020.1756669.","journal-title":"Hum Vaccines Immunother"},{"issue":"18","key":"28336_CR58","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1016\/j.vaccine.2024.05.001","volume":"42","author":"G Danelian","year":"2024","unstructured":"Danelian G, Burton L, Bayley T, Sanchez-Marroquin A, Park J, Manley H, Choi Y, Andrews N, Ladhani S, Earnshaw A, Gritzfeld JF, Trotter C, Panovska-Griffiths J. The impact and cost-effectiveness of pneumococcal immunisation strategies for the elderly in England. Vaccine. 2024;42(18):3838\u201350.","journal-title":"Vaccine"},{"issue":"1","key":"28336_CR59","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12916-024-03277-3","volume":"22","author":"PT de Boer","year":"2024","unstructured":"de Boer PT, van Werkhoven CH, van Hoek AJ, Knol MJ, Sanders EAM, Wallinga J, et al. Higher-valency pneumococcal conjugate vaccines in older adults, taking into account indirect effects from childhood vaccination: a cost-effectiveness study for the Netherlands. BMC Med. 2024;22(1):69. https:\/\/doi.org\/10.1186\/s12916-024-03277-3.","journal-title":"BMC Med"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-026-28336-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-026-28336-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-026-28336-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:08:14Z","timestamp":1789520894000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12889-026-28336-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["28336"],"URL":"https:\/\/doi.org\/10.1186\/s12889-026-28336-7","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"13 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The data used in this model was non-identifiable. This model and its analysis was based on previously published literature and does not contain any new data with human participants or animals. Therefore, no ethical approval was needed.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"St\u00e9phane Fi\u00e9vez, M\u00e9lanie M\u00e9nara, Emmanuelle Blanc and Jeffrey Vietri are employees of Pfizer. Lucile Bellier and Marine Sivignon are employees of Putnam which received funding from Pfizer in connection with the development of this manuscript and study.Lucile Bellier and Marine Sivignon declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"2602"}}